| Bioactivity | Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM[1]. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface[3]. | ||||||
| Invitro | Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin and exhibits a IC50 of 0.94 nM[1].[66Ga]DOTA-E-[c(RGDfK)]2 can be prepared with high radiochemical purity (>97%), specific activity (36-67GBq/μM), in vitro stability, and moderate protein binding. MicroPET imaging up to 24 post-injection showed contrasting tumors reflecting αvβ3-targeted tracer accumulation[2]. | ||||||
| Name | Cyclo(-RGDfK) TFA | ||||||
| CAS | 500577-51-5 | ||||||
| Shortening | Cyclo(RGDFK) | ||||||
| Formula | C29H42F3N9O9 | ||||||
| Molar Mass | 717.69 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Cyclo(-RGDfK) TFA
CAS: 500577-51-5 F: C29H42F3N9O9 W: 717.69
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.